Cancer Genetics Inc

Cancer Genetics — FY2014 Earnings Presentation

13 slides from Cancer Genetics's earnings presentation, Mar 12, 2015

  1. Slide 1: Q4 and Full Year 2014 Earnings Call

    March 12, 2015 Q4 and Full Year 2014 Earnings Call

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potenti

  3. Slide 3: 2014 Revenue Highlights

    2014 Revenue Highlights 3 Cancer Genetics, Inc. | NASDAQ: CGIX | 2014 Earnings Call | March 12, 2015  $10.2M revenue, up 54% Yr./Yr.  Biopharma revenue grew 112% Yr./Yr.  Clinical revenue increased 21% Yr./Yr. Year End Total Revenue ($Mn) $3.0 $4.3 $6.6 10.2 2011 2012 2013 2014 $ 36% CAGR 2014201

  4. Slide 4: Revenues By Category

    Revenues By Category 4 Cancer Genetics, Inc. | NASDAQ: CGIX | 2014 Earnings Call | March 12, 2015 * Direct Bill includes hospitals or facilities are billed directly by CGI and not through insurance ** 3rd Party Insurers include non-Medicare and non-Medicaid insurers 2014 43% 55% 2% Clinical Services

  5. Slide 5: Q4 2014 Financial Highlights

    Q4 2014 Financial Highlights 5  Fourth quarter 2014 revenues were $4.0 million, a 118% increase over fourth quarter 2013 revenues of $1.9 million, and 25% sequential growth over $3.2 million in the third quarter of 2013  Revenue from BioPharma services grew 280% year-over-year during the fourth qu

  6. Slide 6: Full Year 2014 Financial Highlights

    Full Year 2014 Financial Highlights 6  Full year 2014 revenues were $10.2 million, a 54% increase over 2013 revenue  2014 revenue from BioPharma services increased 112% to over $5.6 million during the full year while revenue from Clinical services increased 21% to over $4.4 million during the same

  7. Slide 7: Summary Statement of Operations

    Summary Statement of Operations 7 Income Statement Item ($ in Thousands) 2012 2013 2014 Revenue $4,302 $6,610 $10,199 Gross Profit 373 1,685 1,746 Gross Margin (%) 9% 26% 17% Research & Development (R&D) 2,112 2,190 4,623 Sales & Marketing (S&M) 1,399 1,842 3,964 General & Administrative (G&A) 4,503

  8. Slide 8: Value of Contracts: Biopharma Partners

    Value of Contracts: Biopharma Partners 8 Cancer Genetics, Inc. | NASDAQ: CGIX | 2014 Earnings Call | March 12, 2015 201420132012 Approximate future value of signed contracts with biotechnology and pharma customers for testing and services to support clinical trials.

  9. Slide 9: 2014 Select Highlights

    2014 Select Highlights 9 Cancer Genetics, Inc. | NASDAQ: CGIX | 2014 Earnings Call | March 12, 2015 FHACT® for HPV-Associated Cancer Detection Regulatory Affairs and Patents for FHACT® • US Patent No. 8,865,882 • October 21, 2014 • Patent protection for FHACT®’s 4-marker design • US Patent No. 8,883

  10. Slide 10: Product Launches in NGS

    Product Launches in NGS 10  Launch of CGI FOCUS::NGS™ branded line of Next Generation Sequencing panels  FOCUS::CLL™ NGS panel for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma diagnosis, prognosis and patient management  Selected for use in global clinical trial by a leading biotec

  11. Slide 11: Upcoming Milestones

    Upcoming Milestones 11  MARKET ADOPTION  Increasing covered lives market access through additional payers & health care organizations  Additional international agreements for FHACT® distribution and co-marketing partnerships in key geographies  NEXT GENERATION SEQUENCING PANELS  Launching multi

  12. Slide 12: Reconciliation of Non-GAAP EPS metrics

    Reconciliation of Non-GAAP EPS metrics 12 Cancer Genetics, Inc. | NASDAQ: CGIX | 2014 Earnings Call | March 12, 2015 2014 2013 2014 2013 Net (loss) for diluted earnings per share - GAAP Basis (5,266,261)$ (3,061,389)$ (17,059,919)$ (17,005,553)$ Accelerated stock compensation due to acquisitions 451

  13. Slide 13: Thank You

    Thank You 13 Cancer Genetics, Inc. Meadows Office Complex 201 Route 17 North Rutherford, NJ 07070 (201) 528-9200 www.cancergenetics.com Cancer Genetics, Inc. | NASDAQ: CGIX | 2014 Earnings Call | March 12, 2015

Cancer Genetics — FY2014 Earnings Presentation on 6ix